CO2023000048A2 - Conjugados de citoquina - Google Patents

Conjugados de citoquina

Info

Publication number
CO2023000048A2
CO2023000048A2 CONC2023/0000048A CO2023000048A CO2023000048A2 CO 2023000048 A2 CO2023000048 A2 CO 2023000048A2 CO 2023000048 A CO2023000048 A CO 2023000048A CO 2023000048 A2 CO2023000048 A2 CO 2023000048A2
Authority
CO
Colombia
Prior art keywords
compositions
cytokine conjugates
xten
cytokines
vectors
Prior art date
Application number
CONC2023/0000048A
Other languages
English (en)
Inventor
Volker Schellenberger
Eric Johansen
Angela Henkensiefken
Bryan Irving
Tracy Young
Vibha Chauhan
Valentine Yeung
Original Assignee
Amunix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmaceuticals Inc filed Critical Amunix Pharmaceuticals Inc
Publication of CO2023000048A2 publication Critical patent/CO2023000048A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Abstract

La presente invención se refiere a composiciones que comprenden proteínas biológicamente activas, tales como citoquinas, unidas a polipéptido recombinante extendido (XTEN), ácidos nucleicos aislados que codifican las composiciones y vectores y células hospedantes que contienen los mismos, y a métodos de uso de dichas composiciones en el tratamiento de trastornos y afecciones relacionadas.
CONC2023/0000048A 2020-06-25 2023-01-04 Conjugados de citoquina CO2023000048A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063044335P 2020-06-25 2020-06-25
US202163197944P 2021-06-07 2021-06-07
US202163197875P 2021-06-07 2021-06-07
PCT/US2021/038909 WO2021262985A1 (en) 2020-06-25 2021-06-24 Cytokine conjugates

Publications (1)

Publication Number Publication Date
CO2023000048A2 true CO2023000048A2 (es) 2023-03-27

Family

ID=79281847

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0000048A CO2023000048A2 (es) 2020-06-25 2023-01-04 Conjugados de citoquina

Country Status (12)

Country Link
US (1) US20230265146A1 (es)
EP (1) EP4171609A1 (es)
JP (1) JP2023531496A (es)
KR (1) KR20230042014A (es)
CN (1) CN116096730A (es)
AU (1) AU2021296605A1 (es)
BR (1) BR112022026248A2 (es)
CA (1) CA3180251A1 (es)
CO (1) CO2023000048A2 (es)
IL (1) IL298626A (es)
MX (1) MX2022016389A (es)
WO (1) WO2021262985A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158305A1 (en) * 2022-02-15 2023-08-24 Tagworks Pharmaceuticals B.V. Masked il12 protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
CN117462693A (zh) * 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
WO2017040344A2 (en) * 2015-08-28 2017-03-09 Amunix Operating Inc. Chimeric polypeptide assembly and methods of making and using the same
WO2018213731A1 (en) * 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
JP2021507706A (ja) * 2017-12-21 2021-02-25 アムニクス ファーマシューティカルズ， インコーポレイテッド 放出セグメントおよびそれを含む結合組成物

Also Published As

Publication number Publication date
IL298626A (en) 2023-01-01
BR112022026248A2 (pt) 2023-01-17
AU2021296605A1 (en) 2023-02-23
CN116096730A (zh) 2023-05-09
MX2022016389A (es) 2023-04-11
EP4171609A1 (en) 2023-05-03
KR20230042014A (ko) 2023-03-27
US20230265146A1 (en) 2023-08-24
JP2023531496A (ja) 2023-07-24
AU2021296605A9 (en) 2023-03-09
CA3180251A1 (en) 2021-12-30
WO2021262985A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
HRP20200871T1 (hr) Izmjenjeni rsv f proteini i postupci njihove uporabe
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
AR114445A1 (es) Conjugados de il-15, y sus usos
AR108442A1 (es) Proteínas de fusión gdf15 y usos de estas
PE20200303A1 (es) Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
AR079197A1 (es) Polipeptidos inmunomoduladores derivados de la il-2 y su uso terapeutico en cancer y en infecciones cronicas
Abdi et al. Free IL-12p40 monomer Is a polyfunctional adaptor for generating novel IL-12–like heterodimers extracellularly
DE60125381D1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
BRPI0516350A (pt) proteìna de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de produção de um polipeptìdio, composição, método de modulação de uma imunoresposta em um indivìduo, método para aumentar a meia vida de uma proteìna recombinante em um indivìduo e método para aumentar a eficácia de uma proteìna recombinante em um indivìduo e método de aplicação de uma proteìna terapêutica a um sìtio alvo em um indivìduo
CO2023000048A2 (es) Conjugados de citoquina
BRPI0412799A (pt) imunógeno, composição, ácido nucleico, célula recombinante, métodos para preparar um polipeptìdeo, para induzir um a resposta imune protetora em um paciente e para induzir uma resposta anamnésica em um paciente, e, seqüência de ácido nucleico otimizada de levedura
PE20090483A1 (es) Vectores para la expresion multiple de genes
ZA202208999B (en) Biased il2 muteins methods and compositions
BR112022023288A2 (pt) Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos
AR123978A1 (es) Variantes de la interleucina-18 y métodos de uso
ECSP17075380A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
CO2021005083A2 (es) Distrofinas miniaturizadas y usos de las mismas
PE20231439A1 (es) Proteinas f de hmpv estabilizadas por prefusion
ATE466873T1 (de) Verfahren zur herstellung eines rekombinanten peptids aus spinnengift, und das peptid enthaltende analgetische zusammensetzung
CO2023017358A2 (es) Formulaciones de proteínas quiméricas del factor viii y usos de las mismas
CL2020002246A1 (es) Expresión de proteína de superficie a neumocócica (pspa)